Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methylprednisolone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 7/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 8/20 | 1.00 |
| ▸ | PGR | P06401 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | AR | P10275 | 3/20 | 0.79 |
| ▸ | F2 | P00734 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.70 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.70 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.70 |
| ▸ | TNF | P01375 | 1/20 | 0.70 |
| ▸ | IL6 | P05231 | 1/20 | 0.70 |
| ▸ | GLUL | P15104 | 1/20 | 0.70 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.70 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylprednisolone SCHEMBL16221544 | 1.00 | HIF1A (1.00) | HIF1APGRNR3C1CYP3A4HSD17B10 | |
| Methylprednisolone SCHEMBL5084 | 1.00 | HIF1A (1.00) | HIF1APGRNR3C1CYP3A4HSD17B10 | |
| Methylprednisolone SCHEMBL7160264 | 1.00 | HIF1A (1.00) | HIF1APGRNR3C1CYP3A4HSD17B10 | |
| Methylprednisolone SCHEMBL5085 | 1.00 | HIF1A (1.00) | HIF1APGRNR3C1CYP3A4HSD17B10 | |
| Methylprednisolone SCHEMBL12440040 | 1.00 | HIF1A (1.00) | HIF1APGRNR3C1CYP3A4HSD17B10 | |
| Methylprednisolone SCHEMBL541256 | 1.00 | HIF1A (1.00) | HIF1APGRNR3C1CYP3A4HSD17B10 | |
| Methylprednisolone SCHEMBL13046609 | 1.00 | HIF1A (1.00) | HIF1APGRNR3C1CYP3A4HSD17B10 | |
| Methylprednisolone SCHEMBL13300483 | 1.00 | HIF1A (1.00) | HIF1APGRNR3C1CYP3A4HSD17B10 | |
| Methylprednisolone SCHEMBL21145528 | 1.00 | HIF1A (1.00) | HIF1APGRNR3C1CYP3A4HSD17B10 | |
| Methylprednisolone SCHEMBL193216 | 1.00 | HIF1A (1.00) | HIF1APGRNR3C1CYP3A4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2012 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119120406-A | Imine reductase mutant and application thereof | 仙居两山生物科技有限公司 | 2024-12-13 | — | — | CN | claimed |
| EP-3331650-B1 | METHOD OF MANUFACTURING A VIBRATABLE HEAD FOR AN AEROSOL GENERATOR AND VIBRATABLE HEAD FOR AN AEROSOL GENERATOR | PARI PHARMA GMBH (DE) | 2020-09-30 | — | — | EP | claimed |
| US-10548864-B2 | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2020-02-04 | — | — | US | claimed |
| EP-3169367-B1 | POLY(BETA-AMINO ESTER) CONJUGATES FOR CARTILAGE AGENT DELIVERY AND METHODS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2019-06-05 | — | — | EP | claimed |
| US-10088490-B2 | Assay for analytes using multiple receptors | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2018-10-02 | — | — | US | claimed |
| US-20180064666-A1 | ENHANCED ATRA-RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, AUTOIMMUNE DISEASES, AND ADDICTION CONDITIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2018-03-08 | — | — | US | claimed |
| US-20170112792-A1 | ENHANCED ATRA-RELATED COMPOUNDS DERIVED FROM STRUCTURE-ACTIVITY RELATIONSHIPS AND MODELING FOR INHIBITING PIN1 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2017-04-27 | — | — | US | claimed |
| WO-2016145186-A1 | ENHANCED ATRA-RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, AUTOIMMUNE DISEASES, AND ADDICTION CONDITIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2016-09-15 | — | — | WO | claimed |
| WO-2015143190-A1 | ENHANCED ATRA-RELATED COMPOUNDS DERIVED FROM STRUCTURE-ACTIVITY RELATIONSHIPS AND MODELING FOR INHIBITING PIN1 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2015-09-24 | — | — | WO | claimed |
| US-8740929-B2 | Spacing device for releasing active substances in the paranasal sinus | ACCLARENT, INC. (US) | 2014-06-03 | — | — | US | claimed |
| CN-1092987-C | Delivery of therapeutic agents to receptors using polysaccharides | ADVANCED MAGNETICS INC (US) | 2002-10-23 | — | — | CN | claimed |
| WO-2002006373-A1 | HYDROGEL FILMS AND METHODS OF MAKING AND USING THEREFOR | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2002-01-24 | — | — | WO | claimed |
| WO-2000024388-A2 | COMBINATION OF 5-AMINOSALICYLIC ACID AND A BUDESONIDE, 6-METHYL PREDNISOLONE OR PREDNISOLONE FOR TREATING INFLAMMATORY DISORDERS OF THE INTESTINAL TRACT | DR. FALK PHARMA GMBH (DE) | 2000-05-04 | — | — | WO | claimed |
| CN-1150761-A | Delivery of therapeutic agents to receptors using polysaccharides | ADVANCED MAGNETICS INC (US) | 1997-05-28 | — | — | CN | claimed |
| US-5554386-A | COMPLEXING; INTERNALIZATION INTO CELLS BY RECEPTOR MEDIATED ENDOCYTOSIS | ADVANCED MAGNETICS, INC. (US) | 1996-09-10 | — | — | US | claimed |
| WO-1995034325-A1 | DELIVERY OF THERAPEUTIC AGENTS TO RECEPTORS USING POLYSACCHARIDES | ADVANCED MAGNETICS, INC. (US) | 1995-12-21 | — | — | WO | claimed |
| EP-0301966-B1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING DEGENERATIVE JOINT DISEASE | Trager, Seymour F. (US) | 1992-12-02 | — | — | EP | claimed |
| US-5120720-A | Amorphous complex; stability, water solubility | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 1992-06-09 | — | — | US | claimed |
| WO-1992004888-A1 | PREPARATION OF LIPOPHILE: HYDROXYPROPYL CYCLODEXTRIN COMPLEXES BY A METHOD USING CO-SOLUBILIZERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1992-04-02 | — | — | WO | claimed |
| EP-0311616-B1 | COMBINATIONS OF GAMMA INTERFERONS AND ANTI-INFLAMMATORY OR ANTI-PYRETIC AGENTS FOR TREATING DISEASES | BIOGEN NV (NL) | 1991-09-25 | — | — | EP | claimed |